Financials data is unavailable for this security.
View more
Year on year TriSalus Life Sciences Inc had net income fall 25.11% from a loss of 47.19m to a larger loss of 59.04m despite a 49.31% increase in revenues from 12.40m to 18.51m. An increase in the selling, general and administrative costs as a percentage of sales from 203.43% to 219.04% was a component in the falling net income despite rising revenues.
Gross margin | 87.65% |
---|---|
Net profit margin | -219.71% |
Operating margin | -212.06% |
Return on assets | -220.73% |
---|---|
Return on equity | -- |
Return on investment | -2,149.76% |
More ▼
Cash flow in USDView more
In 2023, TriSalus Life Sciences Inc increased its cash reserves by 25.49%, or 2.46m. Cash Flow from Financing totalled 54.63m or 295.12% of revenues. In addition the company used 50.05m for operations while cash used for investing totalled 2.12m.
Cash flow per share | -1.91 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.8892 |
---|---|
Tangible book value per share | -0.9301 |
More ▼
Balance sheet in USDView more
Current ratio | 2.33 |
---|---|
Quick ratio | 2.04 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼